Market cap
₹71 Cr
Revenue (TTM)
₹1 Cr
P/E Ratio
45.6
P/B Ratio
1.6
Div. Yield
0 %
| IEL | Parmax Pharma | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
71 | 93 | 37 | 28,304 | 21,511 |
Revenue (₹ Cr) |
1 | 28 | 30 | 5,595 | 1,296 |
Net Profit (₹ Cr) |
1.56 | 1.06 | 3.89 | 859.32 | 249.23 |
Net Margin (%) |
70.74 | 3.31 | 11.98 | 14.81 | 18.88 |
RoE (%) |
3.45 | -- | 9.24 | 17.37 | 9.98 |
Price to Earnings |
45.58 | 87.92 | 9.65 | 33.11 | 86.31 |
Price-To-Book |
1.56 | 11.44 | 0.87 | 5.51 | 8.29 |
Income Statement (₹ Cr)
| IEL | Parmax Pharma | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1.47 | 27.56 | 30.32 | 5,594.69 | 1,296.02 |
|
Total Income
|
2.21 | 31.92 | 32.43 | 5,801.47 | 1,320.11 |
|
Total Expenditure
|
0.29 | 29.84 | 26.52 | 4,507.47 | 889.54 |
|
EBITDA
|
1.18 | -2.28 | 3.79 | 1,087.22 | 406.48 |
|
Depreciation
|
0.02 | 1.49 | 0.43 | 79.12 | 78.80 |
|
EBIT
|
1.16 | -3.76 | 3.37 | 1,008.10 | 327.69 |
|
Interest
|
0.07 | 1.23 | 0.24 | 83.89 | 20.95 |
|
Other Income
|
0.74 | 4.36 | 2.11 | 206.78 | 24.09 |
|
Exceptional Items
|
0.00 | 0.00 | 0.00 | 0.00 | -3.66 |
|
Profit before Tax
|
1.83 | -0.63 | 5.24 | 1,130.99 | 327.16 |
|
Provision for Tax
|
0.27 | -1.69 | 1.35 | 271.67 | 77.93 |
|
Profit after Tax
|
1.56 | 1.06 | 3.89 | 859.32 | 249.23 |
Liabilities (₹ Cr)
| IEL | Parmax Pharma | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
45.52 | 9.37 | 43.25 | 5,135.22 | 2,593.77 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | -4.49 | 0.00 |
|
Non-Current Liabilities
|
1.46 | 11.03 | 0.17 | 326.83 | 306.97 |
|
Current Liabilities
|
0.83 | 17.66 | 2.32 | 1,461.60 | 701.52 |
|
Total Liabilities
|
47.10 | 28.05 | 47.88 | 6,523.10 | 3,201.43 |
Assets (₹ Cr)
| IEL | Parmax Pharma | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
12.05 | 13.21 | 2.15 | 3,571.56 | 1,958.51 |
|
Current Assets
|
35.76 | 24.85 | 43.44 | 3,029.24 | 1,370.00 |
|
Total Assets
|
47.10 | 28.05 | 47.88 | 6,523.10 | 3,201.43 |
|
Total Debt*
|
0.90 | 12.06 | 1.81 | 766.57 | 441.66 |
|
Net Current Assets
|
34.93 | 7.19 | 41.12 | 1,567.64 | 668.48 |
|
Contingent Liabilities
|
0.41 | -- | 1.09 | 34.20 | 18.84 |
Cashflow (₹ Cr)
| IEL | Parmax Pharma | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-0.04 | -2.36 | -1.58 | 382.01 | 142.38 |
|
Cash Flow from Investing Activities
|
-25.03 | -0.90 | 2.01 | -963.81 | -619.38 |
|
Cash from Financing Activities
|
-0.07 | 3.81 | -3.44 | 590.26 | 243.86 |
|
Net Cash Inflow / Outflow
|
-25.15 | 0.56 | -3.01 | 8.45 | -233.14 |
Ratios
Profitability Ratios
| IEL | Parmax Pharma | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
ROCE (%)
|
0.74 | -76.70 | 20.17 | 22.42 | 11.65 |
|
ROE (%)
|
3.45 | 0.00 | 9.24 | 17.37 | 9.98 |
|
ROA (%)
|
3.33 | 3.80 | 8.28 | 13.76 | 7.73 |
|
EBIT Margin (%)
|
79.18 | -13.66 | 11.10 | 18.02 | 25.28 |
|
Net Margin (%)
|
70.74 | 3.31 | 11.98 | 14.81 | 18.88 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| IEL | Parmax Pharma | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
261.18 | 76.89 | -8.02 | 25.31 | 30.04 |
|
EBIT Growth (%)
|
225.43 | -24.39 | -7.20 | 15.74 | 26.63 |
|
Net Profit Growth (%)
|
277.30 | 122.34 | -14.22 | 31.78 | 28.03 |
|
EPS Growth (%)
|
671.12 | 125.49 | -14.22 | 27.56 | 24.20 |
|
Book Value Growth (%)
|
0.41 | -154.12 | 14.95 | 29.40 | 10.33 |
Valuation Ratios
| IEL | Parmax Pharma | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
Price / Earnings
|
45.58 | 0.00 | 9.65 | 33.11 | 85.31 |
|
Price / Book Value
|
1.56 | -1.55 | 0.87 | 5.51 | 8.29 |
|
Dividend Yield (%)
|
0.00 | 0.00 | 1.70 | 0.14 | 0.00 |
|
EV/EBITDA
|
60.83 | -6.14 | 9.03 | 25.95 | 53.99 |
|
Market Cap (₹ Cr)
|
74.45 | 10.64 | 33.58 | 22,270.68 | 14,525.20 |
Solvency Ratios
| IEL | Parmax Pharma | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.02 | 1.18 | 0.00 | 0.00 | 0.08 |
|
Short term debt to equity ratio
|
-- | -- | 0.03 | 0.16 | 0.18 |
|
Current Ratio
|
43.09 | 1.41 | 18.71 | 2.07 | 1.95 |
|
Quick Ratio
|
43.09 | 1.13 | 18.70 | 1.52 | 0.93 |
|
Interest Coverage
|
25.70 | 0.49 | 22.64 | 14.48 | 16.62 |
Operating Efficiency Ratios
| IEL | Parmax Pharma | Vasundhara Rasayan | Himadri Speciality | Aether | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
0.00 | 41.75 | 6.02 | 18.34 | 30.12 |
|
Asset Turnover
|
0.03 | 0.99 | 0.65 | 0.90 | 0.40 |
|
Receivable days
|
71.30 | 66.89 | 59.31 | 52.05 | 106.76 |
|
Inventory Days
|
0.00 | 168.22 | 17.38 | 52.79 | 146.98 |
|
Payable days
|
-- | 453.49 | 59.34 | 38.65 | 103.88 |
|
Cash Conversion Cycle
|
-- | -218.39 | 17.35 | 66.19 | 149.86 |